OrganaBio vs. AllCells: GMP Starting Material Comparison

AllCells is one of the most frequently named alternatives when researchers and cell therapy program managers evaluate OrganaBio. Both companies supply leukopaks and GMP-grade starting material for cell therapy programs. The comparison comes up early in vendor evaluations precisely because the product categories overlap substantially on paper. What separates them is not the product category but the infrastructure behind it, and what that infrastructure means for the quality you receive.

This guide compares OrganaBio and AllCells across the variables that matter most for cell therapy starting material selection: processing model and viability data, GMP compliance, same-donor continuity, and what the AllCells acquisition by Discovery Life Sciences means for the cell therapy-specific focus of the company.

Company Backgrounds

OrganaBio is an independent cell therapy CTDMO with owned Cell Processing Center in San Diego (via Excellos), owned GMP manufacturing infrastructure, and CTDMO capabilities that extend to downstream manufacturing through the 2026 Excellos Labs integration. OrganaBio’s operation is built entirely around the cell therapy starting material and manufacturing use case. There is no non-cell-therapy business within OrganaBio. The company’s quality systems, donor network, and processing infrastructure are purpose-built for this vertical.

AllCells was founded in 1999 as a human blood and bone marrow supplier. The company built a large apheresis donor network over its first two decades and became one of the better-known names in leukopak supply. In 2021, AllCells was acquired by Discovery Life Sciences, a multi-service CRO with operations across biospecimen collection, genomics, proteomics, and other research services. As part of DLS, AllCells operates as the apheresis and cell therapy starting material component of a larger diversified biospecimen business.

That context matters because the organizational incentives and quality system focus of a standalone cell therapy starting material company and a component business within a diversified CRO are different. It is not a claim that AllCells’ quality declined after the acquisition. It is an observation that when evaluating a supplier for a multi-year cell therapy program, the organizational structure around the team delivering your starting material is part of the supplier qualification picture.

Processing Infrastructure Compared

AllCells’ Network Approach

AllCells’ primary market positioning emphasizes network scale. Their published claims reference a large apheresis collection network, high collection deliverability rates, and the volume of collections processed since founding. For programs that need geographic coverage across many enrollment sites simultaneously, network scale is a real operational capability.

Network-based processing means that leukapheresis collections are coordinated through affiliated collection sites and processed through a combination of owned and network facilities. The time from collection to processing depends on the logistics of each collection site within the network. Out-of-market collections ship overnight to a central processing facility, following the same model as other large centralized suppliers.

OrganaBio’s Owned CPC Model

OrganaBio’s Cell Processing Centers are owned and operated by OrganaBio, not affiliated through a third-party network. Collections coordinated through OrganaBio’s apheresis program go directly to an owned CPC, with a 30-minute standard for the time from product receipt to the first centrifuge spin. Processing happens under OrganaBio SOPs in OrganaBio facilities by OrganaBio personnel. There is no overnight shipment step for collections within the CPC network’s geographic reach.

The 6-city CPC expansion roadmap extends this model to additional markets. Current West Coast coverage centers on San Diego (via Excellos). Additional markets including Chicago, Houston, and others are in active planning. AllCells’ network has broader current geographic reach. OrganaBio’s owned-facility model has narrower current geographic coverage but higher processing quality per collection within its network.

Viability and Cell Quality Specifications

The distinction between a published minimum specification and documented average performance is the most important number in this comparison. AllCells, like most suppliers, publishes floor specifications for their products. Floor specifications define where quality control releases product, not where typical performance lands. OrganaBio’s greater than 99% average viability for CPC-processed healthy donor material is documented average performance from owned facilities where the time-to-processing variable is controlled. These are different types of numbers measuring different things, and comparing them directly requires understanding that distinction.

For researchers whose experiments depend on PBMC functional capacity rather than viability score alone, the processing timeline correlation matters. Published research has documented that PBMC samples with high viability scores can have significantly impaired functional responses following prolonged handling. The 30-minute OrganaBio standard is the supply chain variable most directly connected to this functional preservation issue.

GMP Starting Material Comparison

Both suppliers offer GMP-grade leukopak products for cell therapy manufacturing. The GMP comparison is less about whether the products are GMP-compliant and more about the structure of the quality system behind the compliance.

AllCells’ GMP operations are part of the Discovery Life Sciences infrastructure. Their GMP products are produced within a multi-service CRO quality system that covers multiple business lines. The GMP quality documentation for cell therapy starting material is one component of a larger QMS covering genomics, proteomics, biospecimen banking, and other services.

OrganaBio’s GMP operations are purpose-built for cell therapy starting material. The quality system is designed specifically for the donor screening, processing, characterization, and release requirements of leukapheresis products for cell therapy manufacturing. There is no non-cell-therapy GMP work being managed within the same quality system.

For IND sponsors conducting supplier qualification audits, the question is not whether a supplier has a GMP QMS. It is whether the QMS was designed for your specific product type, and whether the operational resources behind quality oversight are focused on cell therapy or distributed across unrelated business lines.

Same-Donor RUO-to-GMP Continuity

OrganaBio’s donor program is structured to enable research programs to use material from the same donor in both the research discovery phase and the GMP manufacturing phase. When a cell therapy program characterizes a manufacturing process using RUO starting material and then transitions to GMP production, using the same donor eliminates a comparability variable that would otherwise require bridging studies to address for IND submission.

AllCells does not market same-donor RUO-to-GMP continuity as a program feature. Their donor network operates across many affiliated sites, and maintaining donor continuity between research and clinical phases would require specific program design rather than being a default capability.

For CTDMO scientists and CMC teams planning comparability packages for IND submission, same-donor continuity is a supply chain choice with direct regulatory consequences. It is not a preference. The ability to trace research-phase and GMP-phase manufacturing back to the same donor simplifies the comparability argument. Losing that continuity creates a bridging data burden that same-donor continuity eliminates.

KIR Genotyping

OrganaBio performs KIR genotyping on every donor in the leukopak program. This is the standard donor characterization for NK cell therapy programs, where donor KIR profile predicts NK cell functional activity and is a selection criterion for allogeneic off-the-shelf NK programs.

AllCells does not market KIR genotyping as a standard donor characterization feature across their leukopak portfolio. For NK cell therapy programs that require KIR-typed starting material, OrganaBio’s standard KIR typing on every donor removes the need to request custom characterization for each collection.

The Discovery Life Sciences Acquisition Context

AllCells’ acquisition by Discovery Life Sciences in 2021 changed the organizational context in which AllCells operates. DLS is a multi-service biospecimen and genomics CRO with a broad portfolio that includes oncology tissue, liquid biopsy, nucleic acid isolation, and other services that are not specifically related to apheresis and cell therapy starting material.

The acquisition does not automatically change product quality. It does change organizational priorities, resource allocation, and where senior leadership attention sits. A standalone apheresis company has a leadership team whose entire commercial and operational focus is on apheresis and cell processing. An apheresis business within a diversified CRO has leadership attention distributed across many service lines.

This is worth noting for programs evaluating suppliers for multi-year, multi-phase cell therapy development. Supplier stability and organizational focus matter over a program’s duration. OrganaBio’s independence means the company’s commercial success is tied entirely to the quality of its cell therapy starting material and CTDMO services. There is no other revenue stream that dilutes that focus.

Comparison Summary

When to Choose OrganaBio

OrganaBio is the stronger choice when the program’s priority is processing quality per collection over network scale. Programs with specific KIR genotyping requirements, programs that need same-donor continuity from research phase through GMP, programs where CMC teams want a CTDMO whose quality system is purpose-built for cell therapy starting material, and programs where the decentralized CPC model reduces the overnight shipping variable are the use cases where OrganaBio’s structural choices produce better outcomes.

The Excellos integration means OrganaBio now provides CTDMO services from collection through downstream manufacturing under one quality system. For programs that want to reduce the number of supplier organizations in their supply chain, this end-to-end capability matters.

When AllCells May Fit Better

AllCells’ network scale is a real operational capability for programs that need simultaneous collections across many geographically dispersed sites, particularly sites outside OrganaBio’s current CPC network coverage. If your program needs to run apheresis collections in markets where OrganaBio does not yet have CPC infrastructure, AllCells’ broader network may be the practical answer while the CPC expansion is underway.

Frequently Asked Questions

Is AllCells still independent or is it part of a larger company?

AllCells was acquired by Discovery Life Sciences in 2021. It now operates as the apheresis and cell therapy starting material component of DLS, a multi-service biospecimen and genomics CRO. The AllCells brand name continues in use for the cell therapy products.

How does OrganaBio’s 30-minute processing standard compare to AllCells’ model?

OrganaBio’s 30-minute standard is the time from receipt at the Cell Processing Center to the first centrifuge spin. For collections at or near a CPC, this means processing begins within 30 minutes of collection completion. AllCells’ network model for out-of-market collections involves overnight shipping, with processing typically beginning 18-24 hours after collection. For collections performed at AllCells-affiliated facilities near their processing infrastructure, the timeline is shorter, but OrganaBio’s owned-facility model for in-network collections eliminates the shipping step entirely.

Does OrganaBio have the same geographic collection coverage as AllCells?

Currently, no. AllCells’ multi-site network covers more geographic locations than OrganaBio’s two-CPC current footprint. OrganaBio’s 6-city expansion roadmap will extend the CPC network, but today’s CPC coverage centers on Miami (HQ + HemaCenter), San Diego (Excellos), Irvine, and Bay Area. Programs with enrollment at sites in other markets should discuss how collections in those markets would be handled and what the processing timeline implications are.

What does the AllCells DLS acquisition mean for GMP quality continuity?

The DLS acquisition did not discontinue AllCells’ GMP operations. The practical implications for any individual program depend on how quality oversight and resource allocation have been structured within the combined DLS organization. Sponsors conducting supplier qualification audits for IND submissions should investigate the current organizational structure of the AllCells GMP quality function within DLS, including whether quality leadership and resources are dedicated to the cell therapy line or shared across DLS service lines.

Working With OrganaBio

If you are in an active evaluation comparing OrganaBio and AllCells for a specific program, OrganaBio’s CTDMO team can provide recent lot data, COA examples, and documentation of the CPC quality system for your supplier qualification review. Contact us to discuss your program’s requirements.